Insider Transaction Report

Catherine Owen Adams, a director at Agios Pharmaceuticals, Inc., reported a series of transactions on June 18, 2026. These include the disposal of 2,816 restricted stock units (RSUs) and the acquisition of 2,927 RSUs. Additionally, 14,950 stock options were acquired. All transactions were marked as direct ownership and had a price of $0.00. The RSUs acquired are subject to vesting schedules, with one grant vesting in full on June 18, 2026, and another on June 18, 2027. The stock options vest on June 18, 2027. The filing also notes the acquisition of 2,816 shares of common stock.